Skip to main content
In this Fellows Forum interview, Dr. Samuel Kareff speaks with Dr. Estela Rodriguez, Clinical Research Lead of the Thoracic Site Disease Group at the University of Miami Sylvester Comprehensive Cancer Center, about recent research advances in mesothe...
In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular t...
In this first episode of Oncology Data Advisor's new podcast series, "Exploring Artificial Intelligence in Cancer Care," Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHos...
Oncology Data Advisor® · Predicting Immune-Related Adverse Events Through Machine Learning With Dr. Ofer Sharon of OncoHost In this first episode of Oncology Data Advisor's new podcast series, "Exploring Artificial Intelligence in Cancer C...
Oncology Data Advisor® · New Lung Cancer Screening Guidelines With Brian Whang Recently, the American Cancer Society recommended new lung cancer screening guidelines to shift the focus from quitting smoking, to helping all individuals who ...
Oncology Data Advisor® · Lung Cancer Awareness Month: Global Perspectives With MedNews Week and Oncology Data Advisor In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global ...
The FDA has granted approval to alectinib (Alecensa®, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test...
The FDA has granted approval to amivantamab-vmjw (Rybrevant®, Janssen Biotech, Inc.) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor recept...
The FDA has granted approval to osimertinib (Tagrisso®, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor rec...